Sven Borchmann

7PUBLICATIONS
13CO-AUTHORS
Predictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 30, 2025
Correction: Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

P J Bröckelmann, H Müller, M Fuchs

|Mar 25, 2025
Correlation of progression-free survival and overall survival after treatment for relapsed Hodgkin lymphoma: individual patient data analysis of randomized German Hodgkin Study Group (GHSG) Trials.

P J Bröckelmann, H Müller, M Fuchs

|Oct 12, 2022
Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors.

Sven Borchmann, Carolin Selenz, Mia Lohmann

|Nov 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).

Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic

|Sep 14, 2021
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.

Elena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann

|Sep 09, 2021
Liquid biopsy in Hodgkin lymphoma - moving beyond the proof of principle.

Sven Borchmann

Pageof 2

Frequent Collaborators

3 joint publications

Dennis A Eichenauer

3 joint publications

Wolfram Klapper

3 joint publications

Bastian von Tresckow

2 joint publications

P J Bröckelmann